Using a selective Chk1 inhibitor LY2603618, currently undergoing phase II clinical trial48, we have observed increased elimination of tumor cells lacking de novo pyrimidine synthesis, especially those with p53-deficient status. This evidence concerns the gene TP53 and neoplasm.